- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
- Drug · Genetic
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Pembrolizumab, Folfirinox
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 4 more
- Conditions
- Adenocarcinoma of Pancreas
- Interventions
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX or gemcitabine/abraxane, SBRT
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pancreatic Cancer
- Interventions
- Induction Chemotherapy - FOLFIRINOX, Induction Chemotherapy - Gemcitabine and Nab-Paclitaxel, MR-LINAC Guided Radiotherapy, Surgical Exploration and Resection
- Drug · Radiation · Procedure
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania